Hitachi Medical Systems Europe Holding AG
2
Hitachi Aloka launches two new, highly flexible Diagnostic Ultrasound Systems, ARIETTA Precision and ARIETTA Prologue
mehr
Storys aus Tokyo
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Daiichi Sankyo Launches Once-Daily LIXIANA? Sales Alliance in Europe
Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its European subsidiary, Daiichi Sankyo Europe GmbH Group (headquartered in Munich, Germany; hereafter, DSE), has granted exclusive rights to Merck & Co, Inc., Kenilworth, NJ, USA (NYSE: MRK), known as MSD outside the US and Canada (hereafter, MSD) to market the oral, once-daily anti-coagulant, LIXIANA® (edoxaban), ...
mehrRenault-Nissan Alliance Agrees to Strengthen Its Partnership
Tokyo and Paris (ots/PRNewswire) - Following a Renault Board of Directors meeting in Paris, and a Nissan Board of Directors meeting in Tokyo today, Renault and the Nissan Motor Co., Ltd. issued the following statement from Carlos Ghosn, Chairman and Chief Executive Officer of the Renault-Nissan Alliance: "Today was an important day for the future of the Renault-Nissan Alliance. After months of discussions, I am happy to ...
mehrJT Acquires Natural American Spirit Business Outside the United States
Tokyo (ots/PRNewswire) - Japan Tobacco Inc. (JT) announced today that the JT Group has entered into an agreement with the Reynolds American Inc. group of companies ("RAI") to acquire the Natural American Spirit business outside the United States which includes the trademarks and all outstanding shares of RAI's subsidiaries outside the U.S. which sell the brand. The ...
mehrUK's NICE Recommends Once-daily LIXIANA® (edoxaban) for Preventing Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation
Tokyo (ots/PRNewswire) - The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help prevent stroke and systemic embolism (SE) in patients suffering from the heart rhythm disorder atrial fibrillation (AF).[1] ...
mehrUK's NICE Recommends Once-daily LIXIANA® (Edoxaban) for the Treatment and Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism in Adults
Tokyo (ots/PRNewswire) - The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has today recommended a new treatment to help patients suffering from blood clots in the legs and lungs.[1] Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) ...
mehr
Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE
Tokyo (ots/PRNewswire) - Press release not intended for US and UK media - EU approval paves the way for LIXIANA(R) (edoxaban) to be made available across all European member states - Marketing authorisation is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global ...
mehrDaiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer
Tokyo (ots/PRNewswire) - Daiichi Sankyo announces the initiation of Hokusai-VTE Cancer, a multinational study investigating edoxaban in venous thromboembolism (VTE) associated with cancer Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the initiation of Hokusai-VTE Cancer, a multinational ...
mehrJTI Japan Tobacco International AG
JT Acquires Logic, the Leading Independent US e-Cigarette Company
Geneva (ots/PRNewswire) - - Agreement Gives JT a Global Footprint in the e-Cigarette Market Japan Tobacco Inc. (JT) announced today that it entered into an agreement to acquire Logic Technology Development LLC ("Logic"), one of the leading US e-cigarette brands. Founded in 2010, Logic sells a full range of high quality rechargeable, ready-to-use and disposable e-cigarettes, including the Logic Pro tank system[1], newly ...
mehrDaiichi Sankyo's Once-Daily Lixiana® (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe
Tokyo (ots/PRNewswire) - - The European Committee for Medicinal Products for Human Use recommended approval of once-daily Lixiana(R) - The positive opinion is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global trials of a novel oral anticoagulant in patients with ...
mehrDaiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland
Tokyo (ots/PRNewswire) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana(R) (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism (SE) in ...
mehrJTI Japan Tobacco International AG
JT Acquires Leading E-cigarette Brand E-Lites
Geneva (ots/PRNewswire) - Japan Tobacco Inc. (JT) announced today that it has concluded an agreement to acquire all outstanding shares of Zandera Ltd. ("Zandera"), a leader in e-cigarettes and best known for its E-Lites brand. Founded in 2009, Zandera sells the most recognized range of high quality rechargeable and ready-to-use e-cigarettes in the United Kingdom. "Our investment in Zandera provides the JT Group with an ...
mehr
Astellas Pharma Europe Limited
Astellas Announces Marketing Authorisation Application for XTANDI(TM) (enzalutamide) for Chemotherapy-Naïve Metastatic Prostate Cancer
Tokyo (ots/PRNewswire) - Astellas Pharma Inc. today announces the submission of a variation to amend the Marketing Authorisation Application for XTANDI(TM) (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic ...
mehrMedivation Inc and Astellas Pharma Inc
Medivation and Astellas Announce Final Results from the Phase 3 Prevail Trial of Enzalutamide in Men with Metastatic Prostate Cancer Progressing on Androgen Deprivation Therapy
San Francisco And Tokyo (ots/PRNewswire) - --Study demonstrates statistically significant benefits in overall survival, radiographic progression-free survival, and a delay (17 months) in the time to initiation of chemotherapy-- Medivation Inc. and Astellas Pharma Inc. announced final results on the primary and ...
mehrRenault-Nissan Alliance & Mitsubishi Motors Corporation Explore Wide Ranging Global Product and Technology Cooperation
Amsterdam And Tokyo (ots/PRNewswire) - New projects to drive global product coverage and capacity utilization The Renault-Nissan Alliance and Mitsubishi Motors Corporation today announced their joint intention to explore several new projects covering shared products, technologies and manufacturing capacity among the ...
mehrAstellas Pharma Europe Limited
Medivation and Astellas Announce the Phase 3 PREVAIL Trial of XTANDI?(TM) (Enzalutamide) Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients with Advanced Prostate Cancer
Tokyo And San Francisco (ots/PRNewswire) - - Study will be stopped early and enzalutamide offered to all qualified study participants - 30% Reduction in the Risk of Death, Hazard Ratio = 0.70 ...
mehrDaiichi Sankyo Company (TSE: 4568) and Perosphere Inc
Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban
Mount Kisco, New York And Tokyo (ots/PRNewswire) - Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and ...
mehrHOYA, SEIKO and EPSON; Agreements Executed in the Field of Optical Products Business
Tokyo (ots/PRNewswire) - HOYA Corporation ("HOYA") today executed an agreement with Seiko Epson Corporation ("EPSON") on the transfer of Epson's eyeglass lens development and manufacturing to HOYA. The day of the transfer is planned for the 1st February 2013. HOYA also executed today an agreement with Seiko Holdings Corporation ("SEIKO") on the partial ownership of ...
mehr
NTT Com Acquires 85% Stake in Gyron, Leading UK Data Center Service Provider
Tokyo (ots/PRNewswire) - NTT Communications Corporation (NTT Com) and Gyron Internet Limited (Gyron) jointly announced today that NTT Com acquired 85% of Gyron, a leading provider of data center services in the United Kingdom. NTT Com is further subscribing for additional equity in Gyron to provide capital for planned expansion projects. Gyron, an experienced provider ...
mehrArQule, Inc. and Daiichi Sankyo, Co., Ltd.
Positive Phase 2 Clinical Data With Tivantinib in Hepatocellular Carcinoma to be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology
Woburn, Massachusetts And Tokyo (ots/PRNewswire) - ArQule, Inc. and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line ...
mehrHoya Vision Care Expands its Direct Presence in Brazil
Tokyo (ots/PRNewswire) - ? Hoya Corporation's Vision Care Division, a key player in the global market for ophthalmic lenses, today announced the acquisition of Optotal Hoya S.A., its exclusive partner in Brazil. Optotal operates the largest prescription lens (Rx) laboratory and one of the largest wholesale distribution networks in the ophthalmic lens market in Brazil. HOYA's cooperation with Optotal started in 1992 with a ...
mehrRenesas Mobile Introduces First Integrated LTE Triple-Mode Platform Optimised for Full-Featured, High Volume Smartphones
Tokyo, Japan (ots) - MP5232 Dual 1.5GHz core Communications Processor to Drive LTE Growth with Best-in-Class User Experience for High Volume LTE Smartphones and Tablets Renesas Electronics Corporation (TSE: 6723) and its subsidiary, Renesas Mobile Corporation (http://www.renesasmobile.com), a leading supplier of ...
mehr
Vorherige1234